Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

Abstract Background Surgical procedures impose hemostatic risk to people with hemophilia, which may be minimized by optimal factor (F) replacement therapy. Methods This analysis evaluates the efficacy and safety of extended half‐life factor replacement recombinant FVIII and FIX Fc fusion proteins (r...

Descripció completa

Dades bibliogràfiques

Autors principals:	Pratima Chowdary, Margareta Holmström, Johnny N. Mahlangu, Margaret C. Ozelo, Ingrid Pabinger, K. John Pasi, Margaret V. Ragni, Amy Shapiro, Chris Barnowski, Stefan Lethagen
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2022-07-01
Col·lecció:	Research and Practice in Thrombosis and Haemostasis
Matèries:	factor IX fc fusion protein factor VIII Fc fusion protein hemophilia A hemophilia B recombinant fusion proteins safety
Accés en línia:	https://doi.org/10.1002/rth2.12760
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!